{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:19:26Z","timestamp":1793992766450,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10147-023-02346-6","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:02:17Z","timestamp":1683540137000},"page":"729-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current status of CAR-T cell therapy for pediatric hematologic malignancies"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-5670","authenticated-orcid":false,"given":"Hidefumi","family":"Hiramatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"8","key":"2346_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyx070","volume":"47","author":"K Katanoda","year":"2017","unstructured":"Katanoda K, Shibata A, Matsuda T et al (2017) Childhood, adolescent and young adult cancer incidence in Japan in 2009\u20132011. Jpn J Clin Oncol 47(8):762\u2013771","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"2346_CR2","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86(24):10024\u201310028","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2346_CR3","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20):6106\u20136115","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2346_CR4","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CHJ Lamers","year":"2006","unstructured":"Lamers CHJ, Sleijfer S, Vulto AG et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24(13):e20\u2013e22","journal-title":"J Clin Oncol"},{"issue":"8","key":"2346_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725\u2013733","journal-title":"N Engl J Med"},{"issue":"16","key":"2346_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518","journal-title":"N Engl J Med"},{"issue":"16","key":"2346_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517","journal-title":"N Engl J Med"},{"issue":"5","key":"2346_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448","journal-title":"N Engl J Med"},{"issue":"4","key":"2346_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"2346_CR10","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner RA, Ceppi F, Rivers J et al (2019) Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134(24):2149\u20132158","journal-title":"Blood"},{"issue":"8","key":"2346_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/JCO.20.02477","volume":"39","author":"S Kadauke","year":"2021","unstructured":"Kadauke S, Myers RM, Li Y et al (2021) Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol 39(8):920\u2013930","journal-title":"J Clin Oncol"},{"key":"2346_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642","author":"TW Laetsch","year":"2022","unstructured":"Laetsch TW, Maude SL, Rives S et al (2022) Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00642","journal-title":"J Clin Oncol"},{"issue":"21","key":"2346_CR13","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K et al (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4(21):5414\u20135424","journal-title":"Blood Adv"},{"issue":"26","key":"2346_CR14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA et al (2019) Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood 134(26):2361\u20132368","journal-title":"Blood"},{"key":"2346_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405","author":"RM Myers","year":"2021","unstructured":"Myers RM, Taraseviciute A, Steinberg SM et al (2021) Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01405","journal-title":"J Clin Oncol"},{"issue":"25","key":"2346_CR16","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322\u20133331","journal-title":"Blood"},{"issue":"1","key":"2346_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","volume":"3","author":"MA Pulsipher","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL et al (2022) Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov 3(1):66\u201381","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2346_CR18","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K et al (2021) Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia 35(12):3383\u20133393","journal-title":"Leukemia"},{"issue":"1","key":"2346_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","volume":"28","author":"C Summers","year":"2022","unstructured":"Summers C, Wu QV, Annesley C et al (2022) Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage. Transpl Cell Ther 28(1):21\u201329","journal-title":"Transpl Cell Ther"},{"issue":"15","key":"2346_CR20","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B et al (2021) Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 39(15):1650\u20131659","journal-title":"J Clin Oncol"},{"issue":"12","key":"2346_CR21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"key":"2346_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV (2016) Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 14:357\u2013362","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"2346_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstr\u00edkov\u00e1","year":"2017","unstructured":"Mejstr\u00edkov\u00e1 E, Hrusak O, Borowitz MJ et al (2017) CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J 7(12):659","journal-title":"Blood Cancer J"},{"issue":"10","key":"2346_CR24","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C et al (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24(10):1504\u20131506","journal-title":"Nat Med"},{"issue":"S2","key":"2346_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41409-019-0604-3","volume":"54","author":"E Jacoby","year":"2019","unstructured":"Jacoby E (2019) The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transpl 54(S2):810\u2013814","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2346_CR26","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu XA, Yang J et al (2020) Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv 4(10):2325\u20132338","journal-title":"Blood Adv"},{"issue":"5","key":"2346_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO et al (2020) Optimizing chimeric antigen receptor T-Cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol 38(5):415\u2013422","journal-title":"J Clin Oncol"},{"key":"2346_CR28","doi-asserted-by":"publisher","first-page":"651944","DOI":"10.3389\/fonc.2021.651944","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Chen S, Zhao Z et al (2021) Consolidative hematopoietic stem cell transplantation after CD19 CAR-T cell therapy for acute lymphoblastic leukemia: a systematic review and meta-analysis. Front Oncol 11:651944","journal-title":"Front Oncol"},{"issue":"4","key":"2346_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/bjh.18105","volume":"197","author":"E Jacoby","year":"2022","unstructured":"Jacoby E, Bielorai B, Hutt D et al (2022) Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia. Br J Haematol 197(4):475\u2013481","journal-title":"Br J Haematol"},{"issue":"1","key":"2346_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"key":"2346_CR31","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/OTT.S235882","volume":"13","author":"J Hua","year":"2020","unstructured":"Hua J, Qian W, Wu X et al (2020) Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for a pediatric Ph-like B-ALL patient that relapsed after CART-cell and haplo-HSCT therapy: a case report and review of literature. Onco Targets Ther 13:2311\u20132317","journal-title":"Onco Targets Ther"},{"key":"2346_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01214","author":"T Wang","year":"2022","unstructured":"Wang T, Tang Y, Cai J et al (2022) Coadministration of CD19- and CD22-directed chimeric antigen receptor T-Cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01214","journal-title":"J Clin Oncol"},{"issue":"1","key":"2346_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H et al (2020) Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 13(1):30","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2346_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","volume":"35","author":"K Fousek","year":"2021","unstructured":"Fousek K, Watanabe J, Joseph SK et al (2021) CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35(1):75\u201389","journal-title":"Leukemia"},{"key":"2346_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","volume":"178","author":"JE Jaspers","year":"2017","unstructured":"Jaspers JE, Brentjens RJ (2017) Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther 178:83\u201391","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2346_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms19020340","volume":"19","author":"DH Yoon","year":"2018","unstructured":"Yoon DH, Osborn MJ, Tolar J et al (2018) Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci 19(2):340","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2346_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod DT, Antony J, Martin AJ et al (2017) Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther 25(4):949\u2013961","journal-title":"Mol Ther"},{"key":"2346_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S et al (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013","journal-title":"Sci Transl Med"},{"issue":"9","key":"2346_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jcyt.2015.05.013","volume":"17","author":"S Ramanayake","year":"2015","unstructured":"Ramanayake S, Bilmon I, Bishop D et al (2015) Low-cost generation of good manufacturing practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy 17(9):1251\u20131267","journal-title":"Cytotherapy"},{"issue":"8","key":"2346_CR40","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh H, Manuri PR, Olivares S et al (2008) Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res 68(8):2961\u20132971","journal-title":"Cancer Res"},{"issue":"9","key":"2346_CR41","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jcyt.2014.05.022","volume":"16","author":"S Saito","year":"2014","unstructured":"Saito S, Nakazawa Y, Sueki A et al (2014) Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy 16(9):1257\u20131269","journal-title":"Cytotherapy"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02346-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02346-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02346-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:11:22Z","timestamp":1685524282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02346-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2346"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02346-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}